Spectrum Pharma Dismisses CEO, Makes Leadership Changes
Zacks Investment Research | Dec 17, 2017 09:37PM ET
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced the termination its chief executive officer (CEO) — Rajesh C. Shrotriya — without any cause along with other leadership changes. The company appoints its present chief operating officer (COO), Joseph W. Turgeon, as the new CEO with immediate effect.
Per management, Turgeon will also continue to serve as the president of the company. Currently, he has been elected to the board of directors as well.
Meanwhile, Spectrum promoted Thomas J. Riga — its present executive vice president, chief commercial officer and head of business development — to the post of COO. Furthermore, the company has elected director — Stuart M. Krassner — as the chairman of its board of directors. Notably, all these changes are effective immediately.
Shares of Spectrum Pharma have skyrocketed 185% in the last six months, significantly outperforming the industry ’s gain of 1.2%.
Markedly, Turgeon and Riga have a combined experience of nearly 50 years in the pharmaceutical industry. While Turgeon has 30 years pharma experience including 22 years as vice president of sales at Amgen Inc. (NASDAQ:AMGN) , Riga has carried out a number of executive roles at Amgen, Eli Lilly and Company (NYSE:LLY) and privately held Dendreon for over 15 years.
The lackluster product sales have kept investors focused on pipeline development. The company’s stock has been surging since the beginning of this year backed by its progress with its lead pipeline candidates.
The company is currently developing poziotinib in a phase II study in non-small cell lung cancer patients, Qapzola, in a phase III study in non-muscle invasive bladder cancer and Rolontis in phase III study for treating chemotherapy-induced neutropenia in patients with breast cancer.
The company expects to file a biologics license application for Rolontis by the end of 2018.
All the three candidates hold promise as they target multi-billion dollar market. However, it remains to be seen how the changes at the leadership position will impact the company.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.